A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease.

Trial Profile

A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Prasugrel (Primary) ; Aspirin; Clopidogrel
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms FEATHER
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
    • 10 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top